Intrinsic Value of S&P & Nasdaq Contact Us

Olympus Corporation OCPNY OTC

Other OTC • Healthcare • Medical - Instruments & Supplies • JP • USD

SharesGrow Score
80/100
4/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Olympus Corporation (OCPNY) generated $169.73B in operating cash flow for fiscal year 2022. After capital expenditures of $61.77B, free cash flow was $107.96B.

Free cash flow margin was 12.4% of revenue. Cash conversion ratio was 1.47x, indicating earnings are backed by cash.

The company returned $15.43B in dividends and $30B in share buybacks to shareholders during the period.

Criteria supported by this page:

  • HEALTH (83/100, Pass) — demonstrate the company can comfortably service its debt
  • MOAT (66/100, Partial) — cash flow generation is present but not at levels indicating a wide moat
  • INCOME (55/100) — Cash conversion ratio was 1.47x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 77/100 with 4/7 criteria passed.

SharesGrow 7-Criteria Score
80/100
SG Score
View full scorecard →
VALUE
100/100
Price-to-Earnings & upside
→ Valuation
FUTURE
N/A
No coverage
PAST
100/100
→ Income
HEALTH
83/100
Debt-to-Equity & liquidity
Proven by this page
~
MOAT
66/100
Proven by this page
GROWTH
73/100
→ Income
~
INCOME
55/100
→ Income
Olympus Corporation Cash Flow History
Metric TTM FY2022 FY2021 FY2020 FY2019
Operating Cash Flow $109.42B$169.73B$124.12B$133.54B$66.94B
Capital Expenditure $-64.29B$-61.77B$-59.23B$-65.93B$-61.47B
Free Cash Flow $45.13B$107.96B$64.9B$67.62B$5.48B
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message